Molteni Farmaceutici is born from an innovation: those sterile vials for hypodermic use produced in an old pharmacy in Piazza della Signoria, an absolute novelty on the Italian pharmaceutical market, represented the innovation of a production technique and the starting point of a successful business venture. The company’s energy and vitality in dealing with market changes have made it what it is today: a true excellence in the Italian and European pharmaceutical panorama.
Over the course of its 125 years of history, innovation in Molteni has developed on 3 channels: research and development of new drugs, new technologically advanced systems and an innovative method for human resources development.
>> Read more
A new production line that is the result of the company’s internal development and innovation is one of the last goals achieved over this 125-year business period, besides the production of the Pecsys© system for the innovative nasal spray in the treatment of serious pain, recently introduced in the European Association for Palliative Care (EAPC) and the European Society for Medical Oncology (ESMO) guidelines.
Thanks to the new production line inaugurated at the Scandicci facility near Florence, an innovative drug is under production. It is a nasal spray to control severe pain due to serious oncological pathologies which cannot be relieved with standard therapies. The economic investment exceeds 5 million Euro. The drug is manufactured exclusively for Italy and Europe.
>> Read more
Al fine di aiutare il medico a impostare un corretto piano di cure per combattere la sofferenza inutile, Molteni Farmaceutici >> Read more
Tra le sfide di un mercato sempre più complesso e competitivo raccolte dall’Azienda vi è quella della terapia delle dipendenze >> Read more
Una delle aree terapeutiche di maggior rilievo e prestigio della Molteni Farmaceutici è quella degli anestetici >> Read more